Premium
Halcinonide in the treatment of corticosteroid responsive dermatoses
Author(s) -
LEIBSOHN EUGENE,
BAGATELL FILLMORE K.
Publication year - 1974
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1974.tb06429.x
Subject(s) - medicine , psoriasis , dermatology , triamcinolone acetonide , betamethasone , drug , corticosteroid , pharmacology , surgery
SUMMARY Eighty‐eight patients with bilateral lesions of atopic dermatitis, eczematous dermatitis, neurodcrmatitis or psoriasis were treated, without occlusion, with halcinonide and with betamethasone 17‐valerate creams (0.1%) and evaluated in a double‐blind, paired comparison study. In the forty‐three psoriatic patients, halcinonidc was superior in twenty‐three, betamethasone 17‐valerate was superior in four, both drugs were equally effective in fourteen, and neither drug was effective in two. In the evaluation of all eighty‐eight patients, halcinonide was superior in forty‐two, betamethasone 17‐valerate was superior in eight, both drugs were equally effective in twenty‐nine, and neither drug was effective in nine. The overall superiority of halcinonide to betamethasone 17‐valerate was highly significant (P <0.001). Halcinonide exhibited its superiority each week of the 3‐week study. There were no side effects with either drug. The substitution of a chlorine atom for a hydroxyl group in the 21‐position of the triamcinolone acctonide molecule, and the use of a specifically formulated cream vehicle containing propylene glycol and water, have yielded an extremely active topical anti‐inflammatory drug.